<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03385928</url>
  </required_header>
  <id_info>
    <org_study_id>NTA1702</org_study_id>
    <nct_id>NCT03385928</nct_id>
  </id_info>
  <brief_title>STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units</brief_title>
  <official_title>STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units. A Phase II Randomised, Placebo-controlled, Investigator-driven Trial of Tranexamic Acid Within 2 Hours of Intracerebral Haemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuroscience Trials Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Florey Institute of Neuroscience and Mental Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Neuroscience Trials Australia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective phase II randomised, double-blind, placebo-controlled&#xD;
      investigator-driven trial in acute intracerebral haemorrhage patients. The study has 2 arms&#xD;
      with 1:1 randomisation to either intravenous tranexamic acid or placebo and will test the&#xD;
      hypothesis that in patients with spontaneous ICH, treatment with tranexamic acid within 2&#xD;
      hours of onset will reduce haematoma expansion compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will include patients with acute spontaneous ICH, who are ≥18 years of age and are&#xD;
      eligible for treatment within 2 hours of stroke onset. A sample size of 326 patients is&#xD;
      calculated to give 80% power to detect a large effect size assuming mean relative ICH&#xD;
      haematoma growth of 38% in the placebo arm compared to 19% in the active treatment arm and&#xD;
      standard deviation of 19%, inflated for nonparametric analysis. Adaptive increase in sample&#xD;
      size will be performed if the result of interim analysis of the first 144 patients is&#xD;
      promising, using the methodology of Mehta and Pocock. The maximum sample size is capped at&#xD;
      326. Standard CT for initial diagnosis of suspected stroke patients will be performed.&#xD;
      Neurological impairment and functional scores will be measured by a neurologist or health&#xD;
      care professional trained in their administration. The assessors will be blinded to the&#xD;
      treatment group. Patients eligible for the RCT will be randomised in a 1:1 ratio to receive&#xD;
      either tranexamic acid or placebo stratified by treating centre and utilising randomly&#xD;
      permuted blocks of random size.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study is a prospective phase II randomised, double-blind, placebo-controlled, investigator-driven trial in acute intracerebral haemorrhage patients. The study has 2 arms with 1:1 randomisation to either intravenous tranexamic acid or placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Haematoma growth by 24±6 hours as defined by either ≥33%or ≥6ml increase from baseline ICH volume (mls)</measure>
    <time_frame>24 hours(plus or minus 6 hours)</time_frame>
    <description>Relative ICH haematoma growth</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Haematoma growth by 24±6 hours as defined by ≥33%or ≥6ml increase from baseline in intracerebral haematoma volume, or any increase intraventricular haematoma volume</measure>
    <time_frame>24 hours ±6 hours</time_frame>
    <description>ICH or IVH growth at 24 hours ±6 hours from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute haematoma growth by 24±6 hours</measure>
    <time_frame>24 hours ±6 hours</time_frame>
    <description>ICH growth as defined by either ≥33%or ≥6ml increase from baseline from baseline, adjusted for baseline ICH volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative haematoma growth by 24±6 hours</measure>
    <time_frame>24 hour ±6 hours</time_frame>
    <description>Relative ICH growth volume, adjusted for baseline ICH volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute intraventricular haematoma growth by 24 hours ±6 hours</measure>
    <time_frame>24 hours ±6 hours</time_frame>
    <description>IVH growth at 24 hours ±6 hours from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute intracerebral plus intraventricular haematoma growth by 24±6 hours</measure>
    <time_frame>24 hours ±6 hours</time_frame>
    <description>ICH plus IVH growth from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients with mRS 0-3 or back to pre-stroke level at 3 months</measure>
    <time_frame>90 days ± 7 days</time_frame>
    <description>mRS 0-3 or back to pre-stroke level at 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients with mRS 0-4 or back to pre-stroke level at 3 months</measure>
    <time_frame>90 days ± 7 days</time_frame>
    <description>mRS 0-4 or back to pre-stroke level at 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical shift in mRS at 3 months</measure>
    <time_frame>90 days ± 7 days</time_frame>
    <description>mRS 0-4 or back to pre-stroke level, or mRS 0-3 or back to pre-stroke level (with lowest mRS score being the better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major thromboembolic events (myocardial infarction, ischaemic stroke, or pulmonary embolism) within 3 months</measure>
    <time_frame>3 months from baseline</time_frame>
    <description>Safety outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death within 3 months</measure>
    <time_frame>3 months from baseline</time_frame>
    <description>Safety outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death within 7 days</measure>
    <time_frame>7 days from baseline</time_frame>
    <description>Safety outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">326</enrollment>
  <condition>Intracerebral Haemorrhage</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous tranexamic acid 1000 mg in 100 mL 0.9% NaCl (or in 50ml syringe with 0.9% NaCl) over 10 minutes followed by 1000 mg in 500 mL 0.9% NaCl infusion over 8 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline (0.9% NaCl)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 mls (or in 50ml syringe) intravenous 0.9%NaCl over 10 minutes followed by 500 ml intravenous 0.9% NaCl infusion over 8 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Investigational product given within 2 hours of symptom onset</description>
    <arm_group_label>Tranexamic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Placebo given within 2 hours of symptom onset</description>
    <arm_group_label>Normal Saline (0.9% NaCl)</arm_group_label>
    <other_name>0.9%NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients presenting with an acute ICH&#xD;
&#xD;
          2. Age ≥18 years&#xD;
&#xD;
          3. Treatment can commence within 2 hours of symptom onset (or in patients with unknown&#xD;
             time of symptom onset, the time patient was last known to be well)&#xD;
&#xD;
          4. Consent can be obtained from participant or person responsible. When emergency&#xD;
             treatment procedures have been followed the participant or person responsible will be&#xD;
             asked for consent to continue in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Glasgow coma scale (GCS) total score of &lt;8&#xD;
&#xD;
          2. Brainstem ICH&#xD;
&#xD;
          3. ICH volume &gt;70 ml as measured by the ABC/2 method&#xD;
&#xD;
          4. ICH known or suspected by study investigator to be secondary to trauma, aneurysm,&#xD;
             vascular malformation, haemorrhagic transformation of ischaemic stroke, cerebral&#xD;
             venous thrombosis, thrombolytic therapy, tumour, or infection&#xD;
&#xD;
          5. Any history or current evidence suggestive of venous or arterial thrombotic events&#xD;
             within the previous 12 months, including clinical, ECG, laboratory, or imaging&#xD;
             findings. Clinically silent chance findings of old ischemia are not considered&#xD;
             exclusion.&#xD;
&#xD;
          6. Hereditary or acquired haemorrhagic diathesis or coagulation factor deficiency.&#xD;
&#xD;
          7. Use of heparin, low-molecular weight heparin, GPIIb/IIIa antagonist, or oral&#xD;
             anticoagulation (e.g. warfarin, factor Xa inhibitor, thrombin inhibitor) within the&#xD;
             previous 72 hours.&#xD;
&#xD;
          8. Pregnancy (women of childbearing potential must be tested)&#xD;
&#xD;
          9. Planned surgery for ICH within 24 hours&#xD;
&#xD;
         10. Concurrent or planned treatment with haemostatic agents (e.g. prothrombin complex&#xD;
             concentrate, vitamin K, fresh frozen plasma, or platelet transfusion)&#xD;
&#xD;
         11. Participation in any investigational study in the last 30 days&#xD;
&#xD;
         12. Known terminal illness or planned withdrawal of care or comfort care measures&#xD;
&#xD;
         13. Any condition that, in the judgment of the investigator could impose hazards to the&#xD;
             patient if study therapy is initiated or affect the participation of the patient in&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoffrey Donnan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Florey Institute of Neuroscience and Mental Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Davis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne Health Dept of Neurology &amp; The University of Melbourne Dept of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henry Zhao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne Health Dept of Neurology &amp; The University of Melbourne Dept of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henry Zhao, MD</last_name>
    <phone>+61 3 9342 7000</phone>
    <email>henry.zhao@mh.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michele Sallaberger</last_name>
    <phone>0438 471 423</phone>
    <email>michele.sallaberger@florey.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Worthington</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrew Cheung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Neil Spratt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunshine Coast University Hospital</name>
      <address>
        <city>Birtinya</city>
        <state>Queensland</state>
        <zip>4575</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rohan Grimley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gold Coast University Hospital</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Darshan Shah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Helen Brown</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Timothy Kleinig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philip Choi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Henry Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lauren Sanders</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Geelong</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Benjamin Clissold</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vincent Thijs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Geoffrey Cloud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Davis</last_name>
    </contact>
    <investigator>
      <last_name>Stephen Davis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mobile Stroke Unit</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Henry Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Atte Meretoja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CDHB Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>8140</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Teddy Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palmerston North Hospital</name>
      <address>
        <city>Palmerston North</city>
        <zip>4442</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Karim Mahawish</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wellington Hospital</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anna Ranta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>E-DA Hospital</name>
      <address>
        <city>Kaohsiung City</city>
        <state>Yanchao District</state>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hao-Kuang Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung City</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Der-Yang Cho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jiann-Shing Sheng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Finland</country>
    <country>New Zealand</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 13, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ICH</keyword>
  <keyword>Stroke</keyword>
  <keyword>Cerebrovascular Disorders</keyword>
  <keyword>Brain Diseases</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Tranexamic Acid</keyword>
  <keyword>Antifibrinolytic Agents</keyword>
  <keyword>Fibrin Modulating Agents</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Cardiovascular Agents</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Hematologic Agents</keyword>
  <keyword>Hemostatics</keyword>
  <keyword>Contrast Media</keyword>
  <keyword>Angiography</keyword>
  <keyword>Cerebral Angiography</keyword>
  <keyword>Tomography, X-Ray Computed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

